Impaired Fibroblast Growth Factor 21 (FGF21) Associated with Visceral
Adiposity Leads to Insulin Resistance: The Core Defect in Diabetes
Mellitus

Unnati      Jain; Priyanka      Srivastava; Ashwani      Sharma; Subrata      Sinha; Surabhi      Johari

doi:10.2174/0115733998265915231116043813

Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.

Abstract

The Central nervous system (CNS) is the prime regulator of signaling pathways whose function includes regulation of food intake (consumption), energy expenditure, and other metabolic responses like glycolysis, gluconeogenesis, fatty acid oxidation, and thermogenesis that have been implicated in chronic inflammatory disorders. Type 2 diabetes mellitus (T2DM) and obesity are two metabolic disorders that are linked together and have become an epidemic worldwide, thus raising significant public health concerns. Fibroblast growth factor 21 (FGF21) is an endocrine hormone with pleiotropic metabolic effects that increase insulin sensitivity and energy expenditure by elevating thermogenesis in brown or beige adipocytes, thus reducing body weight and sugar intake. In contrast, during starvation conditions, FGF21 induces its expression in the liver to initiate glucose homeostasis. Insulin resistance is one of the main anomalies caused by impaired FGF21 signaling, which also causes abnormal regulation of other signaling pathways. Tumor necrosis factor alpha (TNF-α), the cytokine released by adipocytes and inflammatory cells in response to chronic inflammation, is regarded major factor that reduces the expression of FGF21 and modulates underlying insulin resistance that causes imbalanced glucose homeostasis. This review aims to shed light on the mechanisms underlying the development of insulin resistance in obese individuals as well as the fundamental flaw in type 2 diabetes, which is malfunctioning obese adipose tissue.

[1]
Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes  2012; 19(2): 81-7.
 [http://dx.doi.org/10.1097/MED.0b013e3283514e13] [PMID: 22327367]

[2]
Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism  2019; 92: 6-10.
 [http://dx.doi.org/10.1016/j.metabol.2018.09.005] [PMID: 30253139]

[3]
Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract  2014; 105(2): 141-50.
 [http://dx.doi.org/10.1016/j.diabres.2014.04.006] [PMID: 24798950]

[4]
Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J Diabetes  2015; 6(6): 850-67.
 [http://dx.doi.org/10.4239/wjd.v6.i6.850] [PMID: 26131326]

[5]
Cai X, She M, Xu M, et al. GLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction. Int J Biol Sci  2018; 14(12): 1696-708.
 [http://dx.doi.org/10.7150/ijbs.27774] [PMID: 30416384]

[6]
 Diabetes Atlas 2021. https://diabetesatlas.org/idfawp/resource files/2021/07/IDF_Atlas_10th_Edition_2021.pdf

[7]
Ndisang JF, Vannacci A, Rastogi S. Insulin resistance, type 1 and Type 2 Diabetes, and related complications. J Diabetes Res  2017; 2017: 1478294.
 [http://dx.doi.org/10.1155/2017/1478294]

[8]
Tan SY, Mei Wong JL, Sim YJ, et al. Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr  2019; 13(1): 364-72.
 [http://dx.doi.org/10.1016/j.dsx.2018.10.008] [PMID: 30641727]

[9]
Janoutová J, Machaczka O, Zatloukalová A, Janout V. Is Alzheimer’s disease a type 3 diabetes? A review. Cent Eur J Public Health  2022; 30(3): 139-43.
 [http://dx.doi.org/10.21101/cejph.a7238] [PMID: 36239360]

[10]
Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol  2022; 10(10): 741-60.
 [http://dx.doi.org/10.1016/S2213-8587(22)00218-2] [PMID: 36113507]

[11]
Ruze R, Liu T, Zou X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol  2023; 14: 1161521.
 [http://dx.doi.org/10.3389/fendo.2023.1161521]

[12]
Dao L, Choi S, Freeby M. Type 2 diabetes mellitus and cognitive function: Understanding the connections. Curr Opin Endocrinol Diabetes Obes  2023; 30(1): 7-13.
 [http://dx.doi.org/10.1097/MED.0000000000000783] [PMID: 36385094]

[13]
Lotfy M, Adeghate J, Kalasz H, Singh J, Adeghate E. Chronic complications of diabetes mellitus: A mini review. Curr Diabetes Rev  2016; 13(1): 3-10.
 [http://dx.doi.org/10.2174/1573399812666151016101622] [PMID: 26472574]

[14]
Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract  2022; 183: 109119.
 [http://dx.doi.org/10.1016/j.diabres.2021.109119] [PMID: 34879977]

[15]
Thunander M, Petersson C, Jonzon K, et al. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract  2008; 82(2): 247-55.
 [http://dx.doi.org/10.1016/j.diabres.2008.07.022] [PMID: 18804305]

[16]
Dahlén AD, Dashi G, Maslov I, et al. Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales. Front Pharmacol  2022; 12: 807548.

[17]
Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One  2014; 9(6): e100777.
 [http://dx.doi.org/10.1371/journal.pone.0100777] [PMID: 24960177]

[18]
Feingold KR, Anawalt B, Blackman MR. Oral and injectable (Noninsulin) pharmacological agents for type 2 diabetes. In: South Dartmouth: MDTextcom, Inc.  2000.

[19]
Dai Y, Dai D, Wang X, Ding Z, Li C, Mehta JL. GLP-1 agonists inhibit ox-LDL uptake in macrophages by activating protein kinase A. J Cardiovasc Pharmacol  2014; 64(1): 47-52.
 [http://dx.doi.org/10.1097/FJC.0000000000000087] [PMID: 24705175]

[20]
Bunck MC, Cornér A, Eliasson B, et al. One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis  2010; 212(1): 223-9.
 [http://dx.doi.org/10.1016/j.atherosclerosis.2010.04.024] [PMID: 20494360]

[21]
Jin T, Weng J. Hepatic functions of GLP-1 and its based drugs: Current disputes and perspectives. Am J Physiol Endocrinol Metab  2016; 311(3): E620-7.
 [http://dx.doi.org/10.1152/ajpendo.00069.2016] [PMID: 27507553]

[22]
McCarthy MI, Zeggini E. Genome-wide association studies in type 2 diabetes. Curr Diab Rep  2009; 9(2): 164-71.
 [http://dx.doi.org/10.1007/s11892-009-0027-4] [PMID: 19323962]

[23]
Valerón PF, de Pablos-Velasco PL. Limitaciones de los fármacos dependientes de insulina para el tratamiento de la diabetes mellitus tipo 2. Med Clin  2013; 141(2): 20-5.
 [http://dx.doi.org/10.1016/S0025-7753(13)70059-9] [PMID: 24444520]

[24]
Kharitonenkov A, DiMarchi R. Fibroblast growth factor 21 night watch: Advances and uncertainties in the field. J Intern Med  2017; 281(3): 233-46.
 [http://dx.doi.org/10.1111/joim.12580] [PMID: 27878865]

[25]
Haas JT, Biddinger SB. Dissecting the role of insulin resistance in the metabolic syndrome. Curr Opin Lipidol  2009; 20(3): 206-10.
 [http://dx.doi.org/10.1097/MOL.0b013e32832b2024] [PMID: 19421055]

[26]
Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annu Rev Physiol  2016; 78(1): 223-41.
 [http://dx.doi.org/10.1146/annurev-physiol-021115-105339] [PMID: 26654352]

[27]
Beenken A, Mohammadi M. The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov  2009; 8(3): 235-53.
 [http://dx.doi.org/10.1038/nrd2792] [PMID: 19247306]

[28]
Liu Y, Liu Y, Deng J, Li W, Nie X. Fibroblast growth factor in diabetic foot ulcer: Progress and therapeutic prospects. Front Endocrinol  2021; 12: 744868.
 [http://dx.doi.org/10.3389/fendo.2021.744868]

[29]
Goetz R, Beenken A, Ibrahimi OA, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol  2007; 27(9): 3417-28.
 [http://dx.doi.org/10.1128/MCB.02249-06] [PMID: 17339340]

[30]
Jones SA. Physiology of FGF15/19. Adv Exp Med Biol  2012; 728: 171-82.
 [http://dx.doi.org/10.1007/978-1-4614-0887-1_11] [PMID: 22396169]

[31]
Wu Y, Ren Z, Zhu S, et al. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway. Acta Pharmacol Sin  2022; 43(6): 1473-83.
 [http://dx.doi.org/10.1038/s41401-021-00786-2] [PMID: 34654875]

[32]
Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta Gene Struct Expr  2000; 1492(1): 203-6.
 [http://dx.doi.org/10.1016/S0167-4781(00)00067-1] [PMID: 10858549]

[33]
Sayers EW, Bolton EE, Brister JR, et al. Database resources of the national center for biotechnology information. Nucleic Acids Res  2022; 50(D1): D20-6.
 [http://dx.doi.org/10.1093/nar/gkab1112] [PMID: 34850941]

[34]
Itoh N, Ornitz DM. Functional evolutionary history of the mouseFgf gene family. Dev Dyn  2008; 237(1): 18-27.
 [http://dx.doi.org/10.1002/dvdy.21388] [PMID: 18058912]

[35]
Staiger H, Keuper M, Berti L, Hrabě de Angelis M, Häring HU. Fibroblast growth factor 21—metabolic role in mice and men. Endocr Rev  2017; 38(5): 468-88.
 [http://dx.doi.org/10.1210/er.2017-00016] [PMID: 28938407]

[36]
Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes  2009; 58(1): 250-9.
 [http://dx.doi.org/10.2337/db08-0392] [PMID: 18840786]

[37]
Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res  2000; 28(1): 27-30.
 [http://dx.doi.org/10.1093/nar/28.1.27] [PMID: 10592173]

[38]
Díaz-Delfín J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F. TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology  2012; 153(9): 4238-45.
 [http://dx.doi.org/10.1210/en.2012-1193] [PMID: 22778214]

[39]
Dai H, Hu W, Zhang L, et al. FGF21 facilitates autophagy in prostate cancer cells by inhibiting the PI3K-Akt-mTOR signaling pathway. Cell Death Dis  2021; 12(4): 303.
 [http://dx.doi.org/10.1038/s41419-021-03588-w]

[40]
Harris TE, Chi A, Shabanowitz J, Hunt DF, Rhoads RE, Lawrence JC Jr. mTOR-dependent stimulation of the association of eIF4G and eIF3 by insulin. EMBO J  2006; 25(8): 1659-68.
 [http://dx.doi.org/10.1038/sj.emboj.7601047] [PMID: 16541103]

[41]
Szczepańska E, Gietka-Czernel M. FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance. Horm Metab Res  2022; 54(4): 203-11.
 [http://dx.doi.org/10.1055/a-1778-4159] [PMID: 35413740]

[42]
Liang Q, Zhong L, Zhang J, et al. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during pro-longed fasting. Diabetes  2014; 63(12): 4064-75.
 [http://dx.doi.org/10.2337/db14-0541] [PMID: 25024372]

[43]
Rui L. Energy metabolism in the liver. Compr Physiol  2014; 4(1): 177-97.
 [http://dx.doi.org/10.1002/cphy.c130024] [PMID: 24692138]

[44]
Christofides A, Konstantinidou E, Jani C, Boussiotis VA. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism  2021; 114: 154338.
 [http://dx.doi.org/10.1016/j.metabol.2020.154338] [PMID: 32791172]

[45]
Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab  2009; 94(9): 3594-601.
 [http://dx.doi.org/10.1210/jc.2009-0111] [PMID: 19531592]

[46]
Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR) gamma: Adiposepredominant expression and induction early in adipocyte differentiation. Endocrinology  1994; 135(2): 798-800.
 [http://dx.doi.org/10.1210/endo.135.2.8033830] [PMID: 8033830]

[47]
Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab  2007; 5(6): 426-37.
 [http://dx.doi.org/10.1016/j.cmet.2007.05.002] [PMID: 17550778]

[48]
Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting. J Clin Invest  1999; 103(11): 1489-98.
 [http://dx.doi.org/10.1172/JCI6223] [PMID: 10359558]

[49]
Wagner KD, Wagner N. Peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol Ther  2010; 125(3): 423-35.
 [http://dx.doi.org/10.1016/j.pharmthera.2009.12.001] [PMID: 20026355]

[50]
Picard F, Auwerx J. PPARγ and G Lucose H Omeostasis. Annu Rev Nutr  2002; 22(1): 167-97.
 [http://dx.doi.org/10.1146/annurev.nutr.22.010402.102808] [PMID: 12055342]

[51]
Dutchak PA, Katafuchi T, Bookout AL, et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell  2012; 148(3): 556-67.
 [http://dx.doi.org/10.1016/j.cell.2011.11.062] [PMID: 22304921]

[52]
Aghanoori MR, Smith DR, Shariati-Ievari S, et al. Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes. Mol Metab  2019; 20: 149-65.
 [http://dx.doi.org/10.1016/j.molmet.2018.11.008] [PMID: 30545741]

[53]
Khera R, Mehan S, Kumar S, Sethi P, Bhalla S, Prajapati A. Role of JAK-STAT and PPAR-Gamma signalling modulators in the prevention of autism and neurological dysfunctions. Mol Neurobiol  2022; 59(6): 3888-912.
 [http://dx.doi.org/10.1007/s12035-022-02819-1] [PMID: 35437700]

[54]
Kubota N, Yano W, Kubota T, et al. Adiponectin stimulates AMPactivated protein kinase in the hypothalamus and increases food intake. Cell Metab  2007; 6(1): 55-68.
 [http://dx.doi.org/10.1016/j.cmet.2007.06.003] [PMID: 17618856]

[55]
Pellegrinelli V, Peirce VJ, Howard L, et al. Adipocyte-secreted BMP8b mediates adrenergic-induced remodeling of the neurovascular network in adipose tissue. Nat Commun  2018; 9(1): 4974.
 [http://dx.doi.org/10.1038/s41467-018-07453-x] [PMID: 30478315]

[56]
Minard AY, Tan SX, Yang P, et al. mTORC1 is a major regulatory node in the FGF21 signaling network in adipocytes. Cell reports  2016; 17(1): 29-36.
 [http://dx.doi.org/10.1016/j.celrep.2016.08.086]

[57]
Ogawa Y, Kurosu H, Yamamoto M, et al. βKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA  2007; 104(18): 7432-7.
 [http://dx.doi.org/10.1073/pnas.0701600104] [PMID: 17452648]

[58]
Su X, Kong Y, Peng D. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease. Clin Chim Acta  2019; 498: 30-7.
 [http://dx.doi.org/10.1016/j.cca.2019.08.005] [PMID: 31419414]

[59]
Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol  2008; 9(5): 367-77.
 [http://dx.doi.org/10.1038/nrm2391] [PMID: 18401346]

[60]
Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev  2018; 98(4): 2133-223.
 [http://dx.doi.org/10.1152/physrev.00063.2017] [PMID: 30067154]

[61]
Cheng L, Wang J, Dai H, et al. Brown and beige adipose tissue: A novel therapeutic strategy for obesity and type 2 diabetes mellitus. Adipocyte  2021; 10(1): 48-65.
 [http://dx.doi.org/10.1080/21623945.2020.1870060]

[62]
Linder K, Arner P, Flores-Morales A, Tollet-Egnell P, Norstedt G. Differentially expressed genes in visceral or subcutaneous adipose tissue of obese men and women. J Lipid Res  2004; 45(1): 148-54.
 [http://dx.doi.org/10.1194/jlr.M300256-JLR200] [PMID: 14563828]

[63]
Cohen P, Spiegelman BM. Brown and beige fat: Molecular parts of a thermogenic machine. Diabetes  2015; 64(7): 2346-51.
 [http://dx.doi.org/10.2337/db15-0318] [PMID: 26050670]

[64]
Poher AL, Altirriba J, Veyrat-Durebex C, Rohner-Jeanrenaud F. Brown adipose tissue activity as a target for the treatment of obesity/insulin resistance. Front Physiol  2015; 6: 4.
 [http://dx.doi.org/10.3389/fphys.2015.00004] [PMID: 25688211]

[65]
Gälman C, Lundåsen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab  2008; 8(2): 169-74.
 [http://dx.doi.org/10.1016/j.cmet.2008.06.014] [PMID: 18680716]

[66]
Justesen S, Haugegaard KV, Hansen JB, Hansen HS, Andersen B. The autocrine role of FGF21 in cultured adipocytes. Biochem J  2020; 477(13): 2477-87.
 [http://dx.doi.org/10.1042/BCJ20200220] [PMID: 32648929]

[67]
Friedman J. 20 years of leptin: Leptin at 20: An overview. J Endocrinol  2014; 223(1): T1-8.
 [http://dx.doi.org/10.1530/JOE-14-0405] [PMID: 25121999]

[68]
Obradovic M, Sudar-Milovanovic E, Soskic S, et al. Leptin and obesity: Role and clinical implication. Front Endocrinol  2021; 12: 585887.
 [http://dx.doi.org/10.3389/fendo.2021.585887] [PMID: 34084149]

[69]
Straub LG, Scherer PE. Metabolic Messengers: Adiponectin. Nat Metab  2019; 1(3): 334-9.
 [http://dx.doi.org/10.1038/s42255-019-0041-z] [PMID: 32661510]

[70]
Atzmon G, Yang XM, Muzumdar R, Ma XH, Gabriely I, Barzilai N. Differential gene expression between visceral and subcutaneous fat depots. Horm Metab Res  2002; 34(11/12): 622-8.
 [http://dx.doi.org/10.1055/s-2002-38250] [PMID: 12660871]

[71]
Zhang XY, Guo CC, Yu YX, Xie L, Chang CQ. Establishment of high-fat diet-induced obesity and insulin resistance model in rats. Beijing Da Xue Xue Bao Yi Xue Ban  2020; 52(3): 557-63.

[72]
Szabo CE, Man OI, Istrate A, et al. Role of adiponectin and tumor necrosis factor-alpha in the pathogenesis and evolution of type 1 diabetes mellitus in children and adolescents. Diagnostics  2020; 10(11): 945.
 [http://dx.doi.org/10.3390/diagnostics10110945] [PMID: 33202729]

[73]
Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine  2016; 86: 100-9.
 [http://dx.doi.org/10.1016/j.cyto.2016.06.028] [PMID: 27498215]

[74]
Bertin E, Nguyen P, Guenounou M, Durlach V, Potron G, Leutenegger M. Plasma levels of tumor necrosis factor-alpha (TNF-alpha) are essentially dependent on visceral fat amount in type 2 diabetic patients. Diabetes Metab  2000; 26(3): 178-82.
 [PMID: 10880890]

[75]
Thissen JP, Underwood L, Maiter D, Maes M, Clemmons DR, Ketelslegers JM. Failure of insulin-like growth factor-I (IGF-I) infusion to promote growth in protein-restricted rats despite normalization of serum IGF-I concentrations. Endocrinology  1991; 128(2): 885-90.
 [http://dx.doi.org/10.1210/endo-128-2-885] [PMID: 1989867]

[76]
Miyazaki Y, Pipek R, Mandarino LJ, DeFronzo RA. Tumor necrosis factor α and insulin resistance in obese type 2 diabetic patients. Int J Obes  2003; 27(1): 88-94.
 [http://dx.doi.org/10.1038/sj.ijo.0802187] [PMID: 12532159]

[77]
Ye J. Mechanisms of insulin resistance in obesity. Front Med  2013; 7(1): 14-24.
 [http://dx.doi.org/10.1007/s11684-013-0262-6] [PMID: 23471659]

[78]
Katsuki A, Sumida Y, Murashima S, et al. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab  1998; 83(3): 859-62.
 [http://dx.doi.org/10.1210/jcem.83.3.4618] [PMID: 9506740]

[79]
Nieto-Vazquez I, Fernández-Veledo S, Krämer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: The link TNF-alpha. Arch Physiol Biochem  2008; 114(3): 183-94.
 [http://dx.doi.org/10.1080/13813450802181047] [PMID: 18629684]

[80]
Alvarez-Crespo M, Csikasz RI, Martínez-Sánchez N, et al. Essential role of UCP1 modulating the central effects of thyroid hormones on energy balance. Mol Metab  2016; 5(4): 271-82.
 [http://dx.doi.org/10.1016/j.molmet.2016.01.008] [PMID: 27069867]

[81]
von Holstein-Rathlou S, BonDurant LD, Peltekian L, et al. FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver. Cell Metab  2016; 23(2): 335-43.
 [http://dx.doi.org/10.1016/j.cmet.2015.12.003] [PMID: 26724858]

[82]
BonDurant LD, Potthoff MJ. Fibroblast growth factor 21: A versatile regulator of metabolic homeostasis. Annu Rev Nutr  2018; 38(1): 173-96.
 [http://dx.doi.org/10.1146/annurev-nutr-071816-064800] [PMID: 29727594]

[83]
Gilroy CA, Capozzi ME, Varanko AK, et al. Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia. Sci Adv  2020; 6(35): eaaz9890.
 [http://dx.doi.org/10.1126/sciadv.aaz9890] [PMID: 32923621]

[84]
Labandeira-Garcia JL, Costa-Besada MA, Labandeira CM, Villar-Cheda B, Rodríguez-Perez AI. Insulin-like growth factor-1 and neuroinflammation. Front Aging Neurosci  2017; 9: 365.
 [http://dx.doi.org/10.3389/fnagi.2017.00365] [PMID: 29163145]

[85]
Kim KH, Lee MS. FGF21 as a stress hormone: The roles of FGF21 in stress adaptation and the treatment of metabolic diseases. Diabetes Metab J  2014; 38(4): 245-51.
 [http://dx.doi.org/10.4093/dmj.2014.38.4.245] [PMID: 25215270]

[86]
Elbein SC. Perspective: The search for genes for type 2 diabetes in the post-genome era. Endocrinology  2002; 143(6): 2012-8.
 [http://dx.doi.org/10.1210/endo.143.6.8831] [PMID: 12021163]

[87]
Chen W, Shen Z, Cai S, Chen L, Wang D. FGF21 promotes wound healing of rat brain microvascular endothelial cells through facilitating TNF-α-mediated VEGFA and ERK1/2 signaling pathway. Adv Clin Exp Med  2021; 30(7): 711-20.
 [http://dx.doi.org/10.17219/acem/133494] [PMID: 34118146]

[88]
Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology  2010; 139(2): 456-63.
 [http://dx.doi.org/10.1053/j.gastro.2010.04.054] [PMID: 20451522]

[89]
Chen Z, Yang L, Liu Y, Huang P, Song H, Zheng P. The potential function and clinical application of FGF21 in metabolic diseases. Front Pharmacol  2022; 13: 1089214.
 [http://dx.doi.org/10.3389/fphar.2022.1089214]

[90]
Liu D, Pang J, Shao W, et al. Hepatic fibroblast growth factor 21 Is involved in mediating functions of liraglutide in mice with dietary challenge. Hepatology  2021; 74(4): 2154-69.
 [http://dx.doi.org/10.1002/hep.31856] [PMID: 33851458]

[91]
Potthoff MJ, Inagaki T, Satapati S, et al. FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA  2009; 106(26): 10853-8.
 [http://dx.doi.org/10.1073/pnas.0904187106] [PMID: 19541642]

[92]
Ameka M, Markan KR, Morgan DA, et al. Liver derived FGF21 maintains core body temperature during acute cold exposure. Sci Rep  2019; 9(1): 630.
 [http://dx.doi.org/10.1038/s41598-018-37198-y] [PMID: 30679672]

[93]
Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. Diabetes Metab Syndr Obes  2020; 13: 3611-6.
 [http://dx.doi.org/10.2147/DMSO.S275898] [PMID: 33116712]

[94]
Charles ED, Neuschwander-Tetri BA, Pablo Frias J, et al. Pegbelfermin (BMS‐986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: Results from a randomized phase 2 Study. Obesity  2019; 27(1): 41-9.
 [http://dx.doi.org/10.1002/oby.22344] [PMID: 30520566]

[95]
Jayawardena R, Jeyakumar DT, Misra A, Hills AP, Ranasinghe P. Obesity: A potential risk factor for infection and mortality in the current COVID-19 epidemic. Diabetes Metab Syndr  2020; 14(6): 2199-203.
 [http://dx.doi.org/10.1016/j.dsx.2020.11.001] [PMID: 33395781]

[96]
Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: From feast to famine. Genes Dev  2012; 26(4): 312-24.
 [http://dx.doi.org/10.1101/gad.184788.111] [PMID: 22302876]

[97]
Caputo M, Pigni S, Agosti E, et al. Regulation of GH and GH signaling by nutrients. Cells  2021; 10(6): 1376.
 [http://dx.doi.org/10.3390/cells10061376] [PMID: 34199514]

[98]
Owen BM, Ding X, Morgan DA, et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab  2014; 20(4): 670-7.
 [http://dx.doi.org/10.1016/j.cmet.2014.07.012] [PMID: 25130400]

[99]
Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Rydén M. FGF21 attenuates lipolysis in human adipocytes - A possible link to improved insulin sensitivity. FEBS Lett  2008; 582(12): 1725-30.
 [http://dx.doi.org/10.1016/j.febslet.2008.04.038] [PMID: 18460341]

[100]
Baruch A, Wong C, Chinn LW, et al. Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans. Proc Natl Acad Sci USA  2020; 117(46): 28992-9000.
 [http://dx.doi.org/10.1073/pnas.2012073117] [PMID: 33139537]

[101]
Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol  2010; 53(5): 934-40.
 [http://dx.doi.org/10.1016/j.jhep.2010.05.018] [PMID: 20675007]

[102]
Turer AT, Scherer PE. Adiponectin: Mechanistic insights and clinical implications. Diabetologia  2012; 55(9): 2319-26.
 [http://dx.doi.org/10.1007/s00125-012-2598-x] [PMID: 22688349]

[103]
Laeger T, Henagan TM, Albarado DC, et al. FGF21 is an endocrine signal of protein restriction. J Clin Invest  2014; 124(9): 3913-22.
 [http://dx.doi.org/10.1172/JCI74915] [PMID: 25133427]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0115733998265915231116043813	Print ISSN 1573-3998
Publisher Name Bentham Science Publisher	Online ISSN 1875-6417

Current Diabetes Reviews

Impaired Fibroblast Growth Factor 21 (FGF21) Associated with Visceral Adiposity Leads to Insulin Resistance: The Core Defect in Diabetes Mellitus

Abstract Play Pause

Related Journals

Related Books

Abstract